Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis.
Indenbaum V, Koren R, Katz-Likvornik S, Yitzchaki M, Halpern O, Regev-Yochay G, Cohen C, Biber A, Feferman T, Cohen Saban N, Dhan R, Levin T, Gozlan Y, Weil M, Mor O, Mandelboim M, Sofer D, Mendelson E, Lustig Y. Indenbaum V, et al. Among authors: feferman t. PLoS One. 2020 Nov 23;15(11):e0241164. doi: 10.1371/journal.pone.0241164. eCollection 2020. PLoS One. 2020. PMID: 33227020 Free PMC article.
Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols.
Barboy O, Bercovich A, Li H, Eyal-Lubling Y, Yalin A, Shapir Itai Y, Abadie K, Zada M, David E, Shlomi-Loubaton S, Katzenelenbogen Y, Jaitin DA, Gur C, Yofe I, Feferman T, Cohen M, Dahan R, Newell EW, Lifshitz A, Tanay A, Amit I. Barboy O, et al. Among authors: feferman t. Nat Cancer. 2024 Mar 1. doi: 10.1038/s43018-024-00734-z. Online ahead of print. Nat Cancer. 2024. PMID: 38429414
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y. Kalaora S, et al. Among authors: feferman t. Cancer Discov. 2018 Nov;8(11):1366-1375. doi: 10.1158/2159-8290.CD-17-1418. Epub 2018 Sep 12. Cancer Discov. 2018. PMID: 30209080 Free PMC article.
Reduced CTL motility and activity in avascular tumor areas.
Manaster Y, Shipony Z, Hutzler A, Kolesnikov M, Avivi C, Shalmon B, Barshack I, Besser MJ, Feferman T, Shakhar G. Manaster Y, et al. Among authors: feferman t. Cancer Immunol Immunother. 2019 Aug;68(8):1287-1301. doi: 10.1007/s00262-019-02361-5. Epub 2019 Jun 28. Cancer Immunol Immunother. 2019. PMID: 31253998 Free PMC article.
34 results